Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity - USD ($)	Total	Public Offering [Member]	Series B Redeemable Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member] Public Offering [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Public Offering [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Beginning Balance at Dec. 31, 2017	$ 39,395,823			$ 61		$ 121,657,587		$ (77,684,839)	$ (4,576,986)
Beginning Balance (in shares) at Dec. 31, 2017			12,177
Beginning Balance at Dec. 31, 2017			$ 9,281,767
Beginning Balance (in shares) at Dec. 31, 2017				608,499
Stock based compensation	762,162					762,162
Vesting and accelerated vesting of restricted stock, net	11,203					11,203
Vesting and accelerated vesting of restricted stock, net (in shares)				284
Exercises of stock options	22,898			$ 1		22,897
Exercises of stock options (in shares)				9,540
Accretion of Series B redeemable convertible preferred stock	(2,894,885)					(2,894,885)
Accretion of Series B redeemable convertible preferred stock			$ 2,894,885
Conversion of Series B redeemable convertible preferred stock into common stock	9,790,367			$ 50		9,790,317
Conversion of Series B redeemable convertible preferred stock into common stock (in shares)			(9,813)
Conversion of Series B redeemable convertible preferred stock into common stock			$ (9,790,367)
Conversion of Series B redeemable convertible preferred stock into common stock (in shares)				502,078
Redemption of Series B redeemable convertible preferred stock for cash and release of embedded derivative	23,292					23,292
Redemption of Series B redeemable convertible preferred stock for cash and release of embedded derivative (in shares)			(2,364)
Redemption of Series B redeemable convertible preferred stock for cash and release of embedded derivative			$ (2,386,285)
Issuance of common stock for the exchange of warrants	3,433,041			$ 32		3,433,009
Issuance of common stock for the exchange of warrants (in shares)				318,668
Issuance of common stock and units, net of offerings cost	26,735,488	$ 10,667,506		$ 491	$ 241	26,734,997	$ 10,667,265
Issuance of common stock and units, net of offering costs (in shares)				4,916,263	2,400,000
Foreign currency translation adjustments	(463,177)								(463,177)
Net loss	(39,171,152)							(39,171,152)
Ending Balance at Dec. 31, 2018	48,312,566			$ 876		170,207,844		(116,855,991)	(5,040,163)
Ending Balance (in shares) at Dec. 31, 2018				9,078,238
Stock based compensation	1,264,231					1,264,231
Vesting and accelerated vesting of restricted stock, net	(47,120)			$ 6		(47,126)
Vesting and accelerated vesting of restricted stock, net (in shares)				(25,691)
Issuance of common stock upon exercise of warrants	30,324			$ 1		30,323
Issuance of common stock upon exercise of warrants (in shares)				11,000
Issuance of common stock and units, net of offerings cost	12,668,784			$ 436		12,668,348
Issuance of common stock and units, net of offering costs (in shares)				4,361,370
Issuance of common stock for acquired in-process research and development	3,791,485			$ 189		3,791,296
Issuance of common stock for acquired in-process research and development (in shares)				1,887,250
Unrealized gain on short term investments	20,007								20,007
Net loss	(20,520,131)							(20,520,131)
Ending Balance at Dec. 31, 2019	$ 45,520,146			$ 1,508		$ 187,914,916		$ (137,376,122)	$ (5,020,156)
Ending Balance (in shares) at Dec. 31, 2019				15,312,167